Improved survival of follicular lymphoma patients in the United States. - Wikidata - awgldk - TriplyDB

Improved survival of follicular lymphoma patients in the United States.

Improved survival of follicular lymphoma patients in the United States.

http://www.wikidata.org/entity/Q50764033

about

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma Follicular lymphoma: 2011 update on diagnosis and management Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.Nature and importance of follicular lymphoma precursors.Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program.High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma.The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma Rituximab maintenance in relapsed or refractory follicular non-Hodgkin's lymphoma: the evidence of its therapeutic value.Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901 Economic impact of disease progression in follicular non-Hodgkin lymphoma.Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8(+) T cells.C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma.Exploring risk factors for follicular lymphoma.Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends Follicular lymphoma: today's treatments and tomorrow's targets.Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.Monoclonal antibodies in lymphoma: the first decade.Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party.Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.Hematopoietic stem cell transplantation for the management of follicular lymphoma

P2860

Q24243100-6921B1B9-49E7-4AC1-B48E-429C7954FD51 Q24633710-37A66F4B-510E-4FCD-BEC4-989E829C4783 Q26851450-01B6C4FA-9C89-4824-94D7-9B0B7410A1CE Q28260230-276365E5-2ADA-43BA-8772-5EE95A926729 Q30538453-91F655D1-8A2C-4793-A9D6-C0847A7CE0D6 Q33416533-F4D2E5E7-ACF7-480D-8230-063113359370 Q33558757-2745B2C1-08A9-4524-BD04-B94518553592 Q33664022-CD1F8442-AC4A-4F37-9709-585415B4CD5B Q33713106-4D2C446F-2AC0-4521-B887-7E5F9E1FFACE Q33873518-F2570B54-6325-4EA7-BCF5-6F3CA9757046 Q34158874-C559B3B4-9C99-442F-8617-33B6E81FDB84 Q34248556-64B7A495-A8B3-4B5D-BB15-ABE35B7B308B Q34418442-32E2FF93-5DD0-4B67-9F19-16359FCB2DAC Q34449805-D5747A92-E6A6-4EAC-B130-4EEC6DDA7EF0 Q34619308-1C89CD8F-4707-495E-A0C6-7E65E89D9727 Q34646321-070DC967-8D6F-4734-91BB-0FD718166093 Q34707136-4C7A4237-5C73-4BA1-B4E1-3F6515DF99A5 Q35056309-55BCB63D-6B21-418B-87C1-675F26AB697E Q35100217-1A0E7464-D449-449E-917E-E457857C6D1C Q35536558-0C2D6615-D366-4801-A41D-DB9B6C07CFA8 Q35798858-F2C8801E-59B0-441B-8D6A-8A9B4F64F07B Q35824964-5EED67A4-BC8A-43DA-972E-74F081A7E723 Q36280146-E8F521B8-5EDA-4CEF-9222-9B377729FDCF Q36463900-4B198621-23BB-430C-9C52-63E1048A13F1 Q36521854-2DF5E424-77A4-4E9F-A247-5CBF0F2C7C68 Q36616696-AE6B7957-B05F-49FF-84D7-99F3B2886510 Q36726780-FCD2E028-F7D0-4858-9716-B24C6D72581B Q36807184-146C3697-332E-4DDC-A701-F07D0DB5028C Q36837124-04C17CD1-F8D4-4C94-9CCD-A1A0CE66F207 Q36842993-6E9725A0-B881-493D-B542-B12C0D86D549 Q36844535-65690088-B820-4088-A818-F3621AD1F3D5 Q36879135-6A34F9A0-019A-41B3-B7A3-B2C839C49631 Q36910325-15810745-BA0D-4149-9D3E-FA67B92F30BF Q36934350-EB79E23F-E7B5-4C77-A5E2-5D6C8D76BE73 Q36961075-91DAF1F5-CF09-4AEB-B859-8166B03B6702 Q36967098-7FDD4C93-E7C1-44CD-89D4-40845F34664F Q36967144-C658F43C-6385-492D-9641-6D67AE7AB081 Q37059428-EFDDA5D3-765C-4916-8204-0FE31B2BA590 Q37083964-22B447FA-B17E-4C21-A84B-7B98C3224BBE Q37194061-6107B918-6852-4012-A1D8-73A718D9099D

P2860

Improved survival of follicular lymphoma patients in the United States.

http://www.wikidata.org/entity/Q50764033

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Improved survival of follicular lymphoma patients in the United States.

@en

Improved survival of follicular lymphoma patients in the United States.

@nl

type

label

Improved survival of follicular lymphoma patients in the United States.

@en

Improved survival of follicular lymphoma patients in the United States.

@nl

prefLabel

Improved survival of follicular lymphoma patients in the United States.

@en

Improved survival of follicular lymphoma patients in the United States.

@nl

P1433

Q50764033-0B82129B-1C75-4734-B8E4-F01588830351

P1476

Q50764033-E9301E1A-091D-4C31-8966-51AF73ABB7F9

P2093

Q50764033-1612F558-51ED-40C6-A48F-AA9FFBDB9E1F

Q50764033-4E351567-4013-4E23-B62C-8655E7A73694

Q50764033-CB2AB8FD-1642-476D-8DD6-6C8AA85416D0

Q50764033-E56F99E5-413F-4D17-A064-D5658908279E

P304

Q50764033-9E04EEED-65B4-4917-A462-2F0E4AFB34F6

P31

Q50764033-622CCCD0-F086-4DD5-A7A4-A2C00DFA8B9B

P356

Q50764033-746AEC42-88A5-4A7E-95C6-1AB6A980D2FF

P407

Q50764033-A794F930-8F3A-4154-832C-4B6CEB9C2D76

P433

Q50764033-DABFB6A1-4343-4F72-A2EF-396296107BEE

P478

Q50764033-90FF53B7-8B70-4BE8-9671-4FB6787980EA

P50

Q50764033-D8C33B7D-45E0-4D47-9771-B891042D6812

Q50764033-DDA840E5-3AEE-410E-8764-D582E96B8836

P577

Q50764033-7DB0BDED-1B16-4E30-A49A-EB2A3AF23287

P698

Q50764033-9DFB8CDC-8DF5-4E47-A588-B7F3489A2F51

P921

Q50764033-0A652DE9-FAA7-44CD-BDA5-59689805E1CC

Q50764033-E51726BF-B679-4748-9DC3-A6D867C108F4

P356

JCO.2005.04.503

P1433

Journal of Clinical Oncology

P1476

Improved survival of follicular lymphoma patients in the United States.

@en

P2093

Charles F Lynch

http://www.w3.org/2001/XMLSchema#string

James E Wooldridge

http://www.w3.org/2001/XMLSchema#string

Valerie L Forman-Hoffman

http://www.w3.org/2001/XMLSchema#string

Wade T Swenson

http://www.w3.org/2001/XMLSchema#string

P304

5019-5026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.04.503

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth A Chrischilles

P577

2005-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15983392

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq